MX2019001471A - Anticuerpos anti-siglec-7 para el tratamiento del cancer. - Google Patents

Anticuerpos anti-siglec-7 para el tratamiento del cancer.

Info

Publication number
MX2019001471A
MX2019001471A MX2019001471A MX2019001471A MX2019001471A MX 2019001471 A MX2019001471 A MX 2019001471A MX 2019001471 A MX2019001471 A MX 2019001471A MX 2019001471 A MX2019001471 A MX 2019001471A MX 2019001471 A MX2019001471 A MX 2019001471A
Authority
MX
Mexico
Prior art keywords
siglec
antibodies
cancer
treatment
compositions
Prior art date
Application number
MX2019001471A
Other languages
English (en)
Inventor
Bebbington Christopher
Korver Wouter
Tomasevic Nenad
EL BADER Suzy
Luehrsen Kenneth
Original Assignee
Allakos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allakos Inc filed Critical Allakos Inc
Publication of MX2019001471A publication Critical patent/MX2019001471A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La invención proporciona métodos y composiciones para el tratamiento de cáncer que usa anticuerpos anti-Siglec-7.
MX2019001471A 2016-08-05 2017-08-04 Anticuerpos anti-siglec-7 para el tratamiento del cancer. MX2019001471A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662371680P 2016-08-05 2016-08-05
PCT/US2017/045641 WO2018027203A1 (en) 2016-08-05 2017-08-04 Anti-siglec-7 antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2019001471A true MX2019001471A (es) 2019-10-30

Family

ID=61073084

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001471A MX2019001471A (es) 2016-08-05 2017-08-04 Anticuerpos anti-siglec-7 para el tratamiento del cancer.

Country Status (13)

Country Link
US (1) US11773162B2 (es)
EP (1) EP3494142A4 (es)
JP (1) JP7137563B2 (es)
KR (1) KR20190035863A (es)
CN (1) CN109790223A (es)
AU (1) AU2017307616A1 (es)
BR (1) BR112019002331A2 (es)
CA (1) CA3032437A1 (es)
EA (1) EA201990296A1 (es)
IL (1) IL264674B2 (es)
MX (1) MX2019001471A (es)
SG (1) SG11201901020RA (es)
WO (1) WO2018027203A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3494142A4 (en) 2016-08-05 2020-04-01 Allakos, Inc. ANTI-SIGLEC-7 ANTIBODIES FOR THE TREATMENT OF CANCER
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
BR112019027353A2 (pt) 2017-07-10 2020-07-14 Innate Pharma agentes, anticorpo, composição farmacêutica, kits, método de modulação de linfócitos, método in vitro de modulação da atividade de linfócitos e composição
US11912766B2 (en) 2018-01-11 2024-02-27 Allakos, Inc. Anti-Siglec-7 antibodies having reduced effector function
JP7425049B2 (ja) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． Ｄｌｌ３結合タンパク質および使用方法
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP2023532768A (ja) 2020-07-07 2023-07-31 バイオエヌテック エスエー Ｈｐｖ陽性癌の治療用ｒｎａ
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
IL309831A (en) 2021-07-13 2024-02-01 BioNTech SE Multispecific binding agents against CD40 and CD137 in combined cancer therapy
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
EP2270148A3 (en) 1999-04-09 2011-06-08 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20070244038A1 (en) 2006-04-12 2007-10-18 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
US8546546B2 (en) * 2007-07-04 2013-10-01 Forerunner Pharma Research Co., Ltd. Anti-Muc 17 antibody
BR112014020826A8 (pt) 2012-02-24 2017-09-19 Stem Centrx Inc Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
AR094271A1 (es) * 2012-12-21 2015-07-22 Aveo Pharmaceuticals Inc Anticuerpos anti-gdf15
EP2999717B1 (en) * 2013-05-21 2018-08-08 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Treatment of mast cell related pathologies
PL3178931T3 (pl) 2014-08-07 2021-06-14 Daiichi Sankyo Company, Limited Przeciwciało anty-orai1
JP2017532025A (ja) 2014-09-10 2017-11-02 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 交差反応性ｓｉｇｌｅｃ抗体
CN108137702B (zh) 2015-08-28 2023-01-06 艾利妥 抗siglec-7抗体及其使用方法
US20190023786A1 (en) * 2016-01-12 2019-01-24 Palleon Pharmaceuticals Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
EP3426688A1 (en) * 2016-03-08 2019-01-16 Innate Pharma Siglec neutralizing antibodies
EP3494142A4 (en) 2016-08-05 2020-04-01 Allakos, Inc. ANTI-SIGLEC-7 ANTIBODIES FOR THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
JP2019526622A (ja) 2019-09-19
US11773162B2 (en) 2023-10-03
CA3032437A1 (en) 2018-02-08
EA201990296A1 (ru) 2019-08-30
JP7137563B2 (ja) 2022-09-14
IL264674B1 (en) 2023-05-01
EP3494142A1 (en) 2019-06-12
IL264674A (es) 2019-03-31
KR20190035863A (ko) 2019-04-03
AU2017307616A1 (en) 2019-02-28
IL264674B2 (en) 2023-09-01
US20190194323A1 (en) 2019-06-27
BR112019002331A2 (pt) 2019-06-18
CN109790223A (zh) 2019-05-21
EP3494142A4 (en) 2020-04-01
WO2018027203A1 (en) 2018-02-08
SG11201901020RA (en) 2019-03-28

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
CR20230163A (es) ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271)
NZ731467A (en) Anti-tim3 antibodies and methods of use
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
NZ738008A (en) Tigit-binding agents and uses thereof
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
MX2019006330A (es) Anticuerpos anti-tau y metodos de uso.
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
TW201613963A (en) Anti-JAGGED1 antibodies and methods of use
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2020006297A (es) Variantes de cd19.
PH12017501864A1 (en) Compositions and methods for treating autism
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.